Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Transition Therapeutics has granted fast track designation to an investigational drug candidate being developed in collaboration with Elan Corporation, for the treatment of Alzheimer's disease.
Subscribe to our email newsletter
The drug, AZD-103/ELND005, is currently being evaluated in multiple phase I clinical studies, and the companies anticipate starting phase II clinical studies around the end of 2007.
Fast track designation is intended to facilitate the development and expedite the review of a drug or biologic if it is intended for the treatment of a serious or life-threatening condition, and it demonstrates the potential to address unmet medical needs for such a condition.